Immutep Quarterly Activities Report Q3 FY25
Provided By GlobeNewswire
Last update: Apr 29, 2025
Media Release
SYDNEY, AUSTRALIA, April 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 31 March 2025 (Q3 FY25).
Read more at globenewswire.com
